Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

NCT00888693 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT00888693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00888693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2008
Completion date
Not reported
Enrollment
81 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia